Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A multicentre, double-blind, placebo-controlled trial with two hundred and ten patients in four groups: Group M (active mesalazine 1.6 g/day plus placebo), Group L (active Lacticaseibacillus (Lactobacillus) paracasei CNCM I 1572 24 billion/day plus placebo), Group LM (active Lactobacillus casei subsp. DG 24 billion/day plus active mesalazine), Group P (placebo). Patients received treatment for 10 days/month for 12 months.
Outcome measures:
Number of patients maintaining remission of symptomatic uncomplicated diverticular disease of the colon
The authors concluded that both cyclic mesalazine and Lactobacillus casei subsp. DG treatments, particularly when given in combination, appear to be better than placebo for maintaining r…